EZH2 and Miyoshi myopathy: Data analysis has not yet been initiated, and the results are expected to be published in 2027.<h4>Conclusions</h4>This unique mechanistic RCT evaluating a TCM formula targeting the PHF19-EZH2-H3K27me3 axis in patients with MM will establish a biomarker-driven framework for integrating TCM with immunotherapy, offering novel strategies for treatment-refractory patients.